Re:Breakthrough drug trial saw cancer vanish in every patien...
by vikramkr on Friday April 05, 2024 @09:05PM
(#39949079)
Depends on if that mechanism of action works for the particular exact set of mutations that the given tumor has (every cancer is essentially unique). Part of the success of the work in that paper is identifying specific markers that indicate that the drug is going to work in that tumor
[ Parent
| on HN ]
Re:Breakthrough drug trial saw cancer vanish in every patien...
by adamredwoods on Saturday April 06, 2024 @01:18PM
(#39953838)
Both dostarlimab and pembro are PD-1 blockers, yet they are labeled for two different cancers. If all tumors have different characteristics, why are these not labeled for all cancers, in general, that display these expressions? Is this part of the game that the FDA plays?
Re:Breakthrough drug trial saw cancer vanish in every patien...
by vikramkr on Saturday April 06, 2024 @02:24PM
(#39954348)
They are:
https://www.fda.gov/news-events/press-announcements/fda-appr...
https://en.wikipedia.org/wiki/Tissue-agnostic_cancer_drug
If by "game" you mean rigorous regulatory process to ensure safety and efficacy, then yeah. Different monoclonal antibodies even with the same target can behave differently. You'd have to specifically design a trial and seek approval for an indication like the one you described. Which people have done and are doing. It's an exciting field of research!